Literature DB >> 33326036

The N2N3 domains of ClfA, FnbpA and FnbpB in Staphylococcus aureus bind to human complement factor H, and their antibodies enhance the bactericidal capability of human blood.

Xinrui Mao1, Junghyun Kim1, QingFeng Zhang1, TingTing Jiang1, Dong Ho Ahn2, Yunjin Jung1, Misao Matsushita3, Taeok Bae4, Bok Luel Lee1.   

Abstract

In the complement system, the opsonin C3b binds to the bacterial cell surface and mediates the opsonophagocytosis. However, the cell-wall protein SdrE of Staphylococcus aureus inhibits the C3b activity by recruiting the complement regulatory protein factor H (fH). SdrE binds to fH via its N-terminal N2N3 domain, which are also found in six other staphylococcal cell-wall proteins. In this study, we report that not only the N2N3 domain of SdrE but also those of ClfA, FnbpA and FnbpB can bind to fH. When immobilized on a microplate, the N2N3 domains recruited fH and enhanced the factor I (fI)-mediated cleavage of C3b. When mixed with fH and S. aureus cells, the N2N3 domains inhibited the fH binding to S. aureus cells and reduced the fI-mediated C3b cleavage on the bacterial cell surface. The F(ab)'2 fragments of the rabbit N2N3 antibodies also inhibited the fH binding to the S. aureus cell surface. When added to human blood, the N2N3 antibodies or the N2N3 domain proteins significantly increased the bactericidal activity. Based on these results, we conclude that, in S. aureus, not only SdrE but also ClfA, FnbpA and FnbpB can contribute to the inhibition of C3b-mediated opsonophagocytosis.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved.

Entities:  

Keywords:  zzm321990 Staphylococcus aureuszzm321990 ; adhesion; cell surface proteins; complement; factor H

Mesh:

Substances:

Year:  2021        PMID: 33326036      PMCID: PMC8254515          DOI: 10.1093/jb/mvaa142

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  29 in total

1.  Rapid and Efficient Genome Editing in Staphylococcus aureus by Using an Engineered CRISPR/Cas9 System.

Authors:  Weizhong Chen; Yifei Zhang; Won-Sik Yeo; Taeok Bae; Quanjiang Ji
Journal:  J Am Chem Soc       Date:  2017-03-02       Impact factor: 15.419

2.  Human complement factor I: its expression by insect cells and its biochemical and structural characterisation.

Authors:  C G Ullman; D Chamberlain; A Ansari; V C Emery; P I Haris; R B Sim; S J Perkins
Journal:  Mol Immunol       Date:  1998-06       Impact factor: 4.407

3.  Optimal conditions for the preparation of Fab and F(ab')2 fragments from monoclonal IgG of different rat IgG subclasses.

Authors:  J Rousseaux; R Rousseaux-Prévost; H Bazin
Journal:  J Immunol Methods       Date:  1983-11-11       Impact factor: 2.303

Review 4.  Challenges for a universal Staphylococcus aureus vaccine.

Authors:  Richard A Proctor
Journal:  Clin Infect Dis       Date:  2012-02-21       Impact factor: 9.079

5.  Quantitative contributions of IgG, IgM and C3 to erythrophagocytosis and rosette formation by peritoneal macrophages, and anti-opsonin activity of dextran sulfate 500.

Authors:  B Wellek; H Hahn; W Opferkuch
Journal:  Eur J Immunol       Date:  1976-06       Impact factor: 5.532

Review 6.  Complement and humoral immunity.

Authors:  Michael C Carroll
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

7.  Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis.

Authors:  Pamela S Hair; Charlene G Echague; Amber M Sholl; Justin A Watkins; Joan A Geoghegan; Timothy J Foster; Kenji M Cunnion
Journal:  Infect Immun       Date:  2010-01-25       Impact factor: 3.441

8.  Model for the complex between protein G and an antibody Fc fragment in solution.

Authors:  K Kato; L Y Lian; I L Barsukov; J P Derrick; H Kim; R Tanaka; A Yoshino; M Shiraishi; I Shimada; Y Arata
Journal:  Structure       Date:  1995-01-15       Impact factor: 5.006

9.  A versatile assay to determine bacterial and host factors contributing to opsonophagocytotic killing in hirudin-anticoagulated whole blood.

Authors:  Erika van der Maten; Marien I de Jonge; Ronald de Groot; Michiel van der Flier; Jeroen D Langereis
Journal:  Sci Rep       Date:  2017-02-08       Impact factor: 4.379

10.  Microbes bind complement inhibitor factor H via a common site.

Authors:  T Meri; H Amdahl; M J Lehtinen; S Hyvärinen; J V McDowell; A Bhattacharjee; S Meri; R Marconi; A Goldman; T S Jokiranta
Journal:  PLoS Pathog       Date:  2013-04-18       Impact factor: 6.823

View more
  4 in total

1.  In silico designed Staphylococcus aureus B-cell multi-epitope vaccine did not elicit antibodies against target antigens suggesting multi-domain approach.

Authors:  Nimat Ullah; Farha Anwer; Zaara Ishaq; Abubakar Siddique; Majid Ali Shah; Moazur Rahman; Abdur Rahman; Xinrui Mao; TingTing Jiang; Bok Luel Lee; Taeok Bae; Amjad Ali
Journal:  J Immunol Methods       Date:  2022-03-25       Impact factor: 2.287

2.  The Role of Nanoscale Distribution of Fibronectin in the Adhesion of Staphylococcus aureus Studied by Protein Patterning and DNA-PAINT.

Authors:  Heba Khateb; Rasmus S Sørensen; Kimberly Cramer; Alexandra S Eklund; Jorgen Kjems; Rikke L Meyer; Ralf Jungmann; Duncan S Sutherland
Journal:  ACS Nano       Date:  2022-07-08       Impact factor: 18.027

3.  Development of Combination Vaccine Conferring Optimal Protection against Six Pore-Forming Toxins of Staphylococcus aureus.

Authors:  QingFeng Zhang; TingTing Jiang; Xinrui Mao; Jae Deog Kim; Dong Ho Ahn; Yunjin Jung; Taeok Bae; Bok Luel Lee
Journal:  Infect Immun       Date:  2021-07-06       Impact factor: 3.441

4.  A Factor H-Fc fusion protein increases complement-mediated opsonophagocytosis and killing of community associated methicillin-resistant Staphylococcus aureus.

Authors:  Megan A G Sage; Katelyn D Cranmer; Michele L Semeraro; Shelby Ma; Elena V Galkina; Y Tran; Keith L Wycoff; Julia A Sharp
Journal:  PLoS One       Date:  2022-03-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.